Results 141 to 150 of about 12,775 (197)

Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market.

JAMA Netw Open
Abdelaziz A, Winn AN, Dusetzina SB, Mitchell AP.   +3 more
europepmc   +1 more source

Bridging the preparedness gap: a systematic review of recommended stockpile items for radiological and nuclear emergencies. [PDF]

BMC Emerg Med
Nocci M, Bortolin M, Hertelendy AJ, Shaikh EA, Davis T, Serale M, Ragazzoni L, Issa F, Romagnoli S, DiGregorio D, Franc JM, Kung JY, Voskanyan A, Ciottone G.   +13 more
europepmc   +1 more source

Successful Treatment of Neutropenia Associated With T-Cell Large Granular Lymphocytic Leukemia Using Fludarabine. [PDF]

Case Rep Hematol
Uemura Y, Togitani K, Kumon Y.
europepmc   +1 more source

Temporal Trends in the Prescription of Biosimilars and the Status of Switching from Original Biologics to Biosimilars at Individual and Institutional Levels in Japan. [PDF]

Ther Innov Regul Sci
Matsumoto M, Kumazawa R, Ishii-Watabe A, Horiguchi I, Mamiya H, Shibata H, Saito Y, Adomi M, Taniguchi Y, Komiyama J, Sakai R, Iwagami M.   +11 more
europepmc   +1 more source

The Optimal Timing and Duration of Daily G-CSF for the Primary Prevention of Febrile Neutropenia in Breast Cancer Patients Undergoing Adjuvant TAC Chemotherapy. [PDF]

Asia Pac J Clin Oncol
Kim Z, Hur SM, Lee JE, Han SW, Jung HI, Kim SY, Lee J, Lim CW.   +7 more
europepmc   +1 more source

Effectiveness and safety of pegylated filgrastim (Pelgraz®) for the prevention of febrile neutropenia during cancer chemotherapy in all-day practice in Germany. [PDF]

Support Care Cancer
Steinmetz T, Jungberg P, Guth D, Knoblich J, Fietz T, Göhler T, Reiser M, Totzke U, Bernhardt K.   +8 more
europepmc   +1 more source

Efficacy and Safety of Pegfilgrastim in Patients With Severe Congenital Neutropenia. [PDF]

EJHaem
Movahedi M, Moradi L, Alizadeh Z, Yazdi MT, Dehbashi S, Shoormasti RS, Maddah M, Razaghian A, Hamidieh AA, Shariat M, Houshmand M, Alirezaee A, Akbari M, Fazlollahi MR, Pourpak Z.   +14 more
europepmc   +1 more source

Targeting Leukopoiesis: Pharmacological and Biotechnological Strategies for the Treatment of Leukopenia. [PDF]

Biomedicines
Baktybayeva L, Kaldybayeva AB, Sokolenko A, Tursynova B, Ten AY, Daulet G, Svambayev E, Thevis M, Yu VK, Tassibekov KS.   +9 more
europepmc   +1 more source

Cost comparison between PAV and ICE treatment with peripheral blood progenitor cells (PBPC) reinfusion in small-cell lung cancer (SCLC) [PDF]

, 2017
Leyvraz, S., Perey, L., Rollier, P., Wasserfallen, J.-B   +3 more
core  

Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer. [PDF]

JNCI Cancer Spectr
Ali A, Barlow WE, Moore HCF, Hobday TJ, Isaacs C, Salim M, Albain KS, Chew HK, Burton GV, Srkalovic G, McGregor BA, Flaherty LE, Lew DL, Gralow JR, Hortobagyi GN, Sharma P, Pusztai L, Budd GT.   +17 more
europepmc   +1 more source